5.02
-0.07(-1.38%)
Currency In USD
| Previous Close | 5.09 |
| Open | 5.11 |
| Day High | 5.18 |
| Day Low | 5.02 |
| 52-Week High | 41.22 |
| 52-Week Low | 4.6 |
| Volume | 99,915 |
| Average Volume | 164,615 |
| Market Cap | 12.66M |
| PE | -0.39 |
| EPS | -12.93 |
| Moving Average 50 Days | 5.7 |
| Moving Average 200 Days | 10.37 |
| Change | -0.07 |
If you invested $1000 in Imunon, Inc. (IMNN) 10 years ago, it would be worth $0.84 as of October 20, 2025 at a share price of $5.02. Whereas If you bought $1000 worth of Imunon, Inc. (IMNN) shares 5 years ago, it would be worth $39.14 as of October 20, 2025 at a share price of $5.02.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
GlobeNewswire Inc.
9 hours ago
Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025 Program will feature presentations from ovarian cancer thought leaders, Phase 3 study investigators, oncology and statistical exper
IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
GlobeNewswire Inc.
Oct 17, 2025 12:10 PM GMT
Company seeks strategic partners to advance novel PlaCCine technology LAWRENCEVILLE, N.J., Oct. 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and eval
IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
GlobeNewswire Inc.
Oct 14, 2025 12:20 PM GMT
Prestigious European Society for Medical Oncology Conference “trials-in-progress” session Pivotal OVATION 3 trial of its DNA-mediated immunotherapy in newly diagnosed patients underway Company on track with established plans to accelerate patient rec